The patients had previously treated inoperable or postoperatively relapsed NSCLC and received activated DCs pulsed with either autologous tumor lysates or peptide antigens (WT1, MUC1, CEA) matched to their HLA-A type (48). This evidence concerns the gene HLA-A and neoplasm.